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The EMPA-REG outcome study: critical 
appraisal and potential clinical implications
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Abstract 
Diabetes health care professionals have to face a study with results of incomparable success in secondary and tertiary 
cardiovascular disease prevention. In the past, no studies in patients with type 2 diabetes resulted to be successful in 
inducing an improvement of cardiovascular prognosis, no matter whether they were focused on a target, on life-
style or on pharmacological intervention. On a clinical perspective, should the diabetologist’s way to think about the 
anti-diabetic therapy of patients on secondary cardiovascular prevention change based on the results of Empa-Reg 
outcome? Due to the complexity of the clinical picture of patients with type 2 diabetes, a tailored therapy based on 
targets, complications, co-morbidity, familial and social environment, personal and cultural features must be con-
ceived and applied in starting pharmacological therapy; however, the question whether should we consider empa-
gliflozin as first choice therapy in individuals with type 2 diabetes exposed to high cardiovascular risk, the Empa-Reg 
outcome-like patient, awaits now for an answer. Waiting for data confirming the results of the Empa-Reg outcome 
study, this report goes through the good reasons in support of this way of thinking, but at the same time explores the 
many unanswered questions raising potential concerns about this clinical choice.
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Brief summary of the study
Aim and patients
  • Aim: To test the non-inferiority of empagliflozin vs 
placebo in terms of cardiovascular (CV) safety.
  • Patients: 7020 type 2 diabetes (T2DM) individuals 
with established CV disease (defined as the pres-
ence of  ≥1 of the following: history of myocardial 
infarction; documented multi-vessel coronary artery 
disease; documented single-vessel coronary artery 
disease with  ≥50  % luminal narrowing plus posi-
tive non-invasive stress test for ischemia or recent 
hospital discharge for unstable angina; documented 
unstable angina; history of ischemic or hemorrhagic 
stroke; occlusive peripheral artery disease), rand-
omized to placebo, empagliflozin 10 or 25 mg as add-
on to the usual therapy.
  • Patients allocated in the three arms were comparable 
for age, gender, BMI and HbA1c; blood pressure (BP) 
and LDL-cholesterol levels (mean 135/77  mmHg 
and 85–86 mg/dl, respectively) were in a reasonably 
good control; 95 % of them assumed antihypertensive 
drugs, 80 % hypolipidemic drugs and 83 % anti-plate-
lets drugs.
  • Median treatment duration: 2.6 years; median obser-
vation time 3.1 years.
  • Statistical analysis: intention-to-treat, comparing 
response to empagliflozin 10 and 25  mg vs placebo 
in all subjects receiving at least one treatment dose; 
non-inferiority analysis, with a HR border of 1.3 vs 
placebo for primary and secondary endpoint; superi-
ority was tested as eventual following step.
Results
  • HbA1c At the end of the study HbA1c reduction was 
0.24 % with 10 mg and 0.36 % with 25 mg empagliflo-
zin vs placebo.
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  • Body weight Patients randomized to empagliflo-
zin showed a significant reduction in body weight 
(2–3 kg with empagliflozin 25 mg).
  • Arterial BP and heart rate Empagliflozin induced a 
prompt reduction of systolic BP (4–6 mmHg vs pla-
cebo at week 16), which was maintained along the 
time. At the end of the study diastolic BP did not dif-
fer from placebo. A higher percent of placebo-treated 
patients required a potentiation of the background 
anti-hypertensive therapy. No difference in the heart 
rate was observed.
  • Lipid profile and uric acid Active treatment induced 
an initial raise in LDL-cholesterol (3–4 mg/dl vs pla-
cebo), which resulted to be negligible after 52 weeks. 
HDL-cholesterol showed a similar trend in the three 
arms. The uricosuric effect of empagliflozin was con-
firmed.
The main results of the study in terms of CV endpoints 
are shown in Table 1. The effects on hard endpoints did 
not differ in the two empagliflozin arms.
The Empa‑Reg outcome is a rewarding study 
with respect to other clinical trials comparing a specific 
anti‑hyperglycemic drugs vs placebo in terms of CV 
endpoints
It is difficult to compare studies performed in different 
historical periods, with different aims, and in patients 
with different clinical characteristics and concomitant 
treatments; however, an attempt to compare Empa-Reg 
outcome [1] with recent clinical studies aimed at assess-
ing non inferiority of other novel anti-diabetic drugs 
respect to traditional, established therapies, is imperative.
The PROactive study tested the efficacy of pioglita-
zone in reducing CV morbidity and mortality in high CV 
risk T2DM patients [2]. The primary endpoint (all-cause 
mortality, non-fatal MI, non-fatal stroke, acute coro-
nary syndrome, revascularization procedures or lower 
limb amputation) was not achieved, in contrast with a 
matched secondary endpoint (CV death, MI, stroke). The 
study was characterized by an excess of non-fatal heart 
failure (HF) but it should be emphasized that HF was not 
an adjudicated end-point and that cases of HF resulted to 
have fewer CV events than those observed in the placebo 
group, raising doubt about the incidence of a true HF 
which could be misclassified in the place of peripheral 
edema. Moreover, the only endpoint with unfavorable 
outcome was the procedure of peripheral revasculari-
zation, in contrast with the effect on MACE which was 
consistently a positive one.
The Origin study tested the efficacy of glargine in 
reducing CV morbidity in T2DM patients with whatever 
background therapy, including insulin [3]. Characteristics 
of the participants were different from those of Empa-Reg 
outcome, being patients with altered glucose tolerance or 
recent onset diabetes even though approximately 60 % of 
them were on secondary CV prevention. The trial gen-
erated a neutral result in terms of coprimary endpoints 
(nonfatal MI, nonfatal stroke, or death from CV causes 
and these events plus revascularization or hospitalization 
for heart failure.), even if it should be underlined that the 
daily insulin use resulted to be about 30 IU per day, likely 
due to very short duration of the disease. Some patients, 
especially those with a longer duration, may require a 
significantly higher amount of insulin and in our opinion 
this condition remains to be tested in terms of CV safety.
Table 1 Cardiovascular results of the Empa-Reg outcome study
Primary endpoint: standard 3 endpoint-MACE (CV death, non-fatal myocardial infarction (MI), non-fatal stroke); pre-specified key secondary endpoints: time to first 
event (CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina)
N.A. not applicable
Empagliflozin (all together) Placebo HR 95 % CI Non inferiority Superiority
Primary endpoint 490/4687 (10.5 %) 282/2333 (12.1 %) 0.86
0.74–0.99
P < 0.001 P = 0.04
Key secondary endpoint 599/4687 (12.8 %) 333/2333 (14.3 %) 0.89
0.78–1.01
P < 0.001 P = 0.08
 Cardiovascular death 172/4687 (3.7 %) 137/2333 (5.9 %) 0.62
0.49–0.77
N.A. P < 0.001
 Non-fatal myocardial infarction 213/4687 (4.5 %) 121/2333 (5.2 %) 0.87
0.70–1.09
N.A. P = 0.22
 Non-fatal stroke 150/4687 (3.2 %) 60/2333 (2.6 %) 1.24
0.92–1.67
N.A. P = 0.16
Heart failure 126/4687 (2.7 %) 95/2333 (4.1 %) 0.65
0.50–0.85
N.A. P = 0.002
All-cause death 269/4687 (5.7 %) 194/2333 (8.3 %) 0.68
0.57–0.82
N.A. P = 0.001
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Savor-TIMI [4], Examine [5] and Tecos [6] tested the 
effects of the DPP-IV inhibitors saxagliptin, aloglip-
tin and sitagliptin on CV safety, to demonstrate their 
non-inferiority with respect to placebo, as requested by 
regulatory authorities. Recruited patients differed for 
clinical characteristics: high CV risk patients in Savor-
TIMI; individuals with recent acute coronary syndrome 
in Examine; relatively low CV risk patients in Tecos. 
We interpret the general findings of these studies as a 
demonstration of DPP-IV inhibitors neutrality on CV 
risk, though a higher risk of hospitalization for HF was 
detected in SAVOR-TIMI and for some authors, based 
on retrospective calculations of the sample size, also 
in Examine. These correlative findings highlighted the 
potential relation between anti-hyperglycemic therapies 
and risk of HF, probably due to the link with the weight 
gain often associated with this treatment [7]. More 
recently at least three very large studies reported no 
effects of DPP-IV inhibitors when tested retrospectively 
in the clinical setting [8, 9] or very small effects [10].
Studies evaluating the effects of GLP-1 analogues will 
hopefully contribute to clarify this important issue. At 
this stage Elixa [11], performed in patients with recent 
acute coronary syndrome, documented the CV safety of 
lisixenatide when compared to placebo, and we are now 
waiting for the publication of the results of the LEADER 
trial, also testing CV safety of one of another GLP1-RA, 
liraglutide, which is expected in the next few weeks.
EMPA REG outcome is a relevant success also with respect 
to trials comparing conventional vs intensive strategies 
of glucose control on CV endpoints
Since the UKPDS study has been published [12], the 
international community is still debating whether or not 
optimizing glucose control could reduce CV risk. To 
address this question, three main large randomized clini-
cal trials were completed, aimed at verifying whether or 
not an improved metabolic control (irrespective of how 
this was obtained) could be associated with a better CV 
outcome: ACCORD [13], ADVANCE [14] and VADT 
[15]. It is well known that these studies have generated 
negative results and frustration, even if they resulted to 
be very useful in inducing a change in the vision of how 
we have to treat our patients, emphasizing the need for a 
“tailored therapy” able to address the individual needs of 
each single patient, especially with respect to the targets 
to pursue.
A common thinking is that an intensive anti-hyper-
glycemic therapy can be deleterious on mortality rate 
of frail individuals, therefore neutralizing potential CV 
benefits [13, 15]; however, it should be noticed that the 
prolonged observation of the individuals participating 
to two of those trials [16, 17] detected, in the post-trial 
observational period, that patients treated more inten-
sively had a reduced CV risk which took longer than it 
was thought, confirming the previously reported and 
similar findings of the follow-up of the UKPDS study 
[18].
Also when combined physical exercise and nutritional 
therapy were the selected strategy to improve glucose 
control, as it was tested in the Look Ahead study, a CV 
benefit could not be detected [19]. Only the PREDIMED 
study [20], which tested the cardiovascular impact of the 
Mediterranean Diet, reported some positive results. It 
this study 7447 persons at high CV risk (with and with-
out diabetes), but without CV disease at baseline were 
randomized to three different dietary regimens: standard 
traditional diet, Mediterranean diet enriched with olive 
oil or with nuts and almonds. Primary end-point was 
the classical composite cardiovascular death, non fatal 
MI and non fatal stroke. Even if the nutritional inter-
vention had no effect on mortality, it showed a clear-cut 
positive effect on CV events which could be observed 
early during the observational period suggesting that the 
nutritionally-induced benefit could be mediated via and 
anti-inflammatory effect.
The mechanisms by which empagliflozin determined the 
CV protection observed in the Empa‑Reg outcome remain, 
so far, obscure
Empa-Reg outcome is a successful clinical study, opening 
novel scenarios but also leaving unsolved several ques-
tions. Mechanistically, it is unclear how the treatment 
could determine such CV benefit. Several candidates 
might be taken into consideration.
Anti-hyperglycemic effect in our opinion the hypothesis 
that the beneficial CV impact could be mediated via the 
anti-hyperglycemic effect is weak because the difference 
in HbA1c levels during the study between empagliflo-
zin treatment and placebo was too small to explain the 
outcome. More importantly, the rapid onset of the pro-
tective effect of the treatment in the empagliflozin arms 
seems to be not compatible with a glycemic effect, which 
is supposed to take longer time as discussed above [16–
18]; such effect has been explained with the concept of 
“metabolic memory”, which was detected years after the 
intervention, not in few weeks/months, as observed in 
Empa-Reg outcome. However empagliflozin has recently 
shown a fast (24 h) efficacy in reducing post-prandial glu-
cose and improving metabolic control in Japanese T2DM 
individuals [21].
Weight loss similar explanations minimize the possibil-
ity that the positive effect could be related to the weight 
loss. Also in this case the small difference among the 
groups in terms of body weight change does not seem 
sufficient to explain such a large and rapid effect on CV 
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mortality; however, we should not forget that, in these 
high CV risk patients, rapid weight gain, potentially 
reflecting fluid retention, can be considered a “proxy” 
for the risk to develop HF [7]. However, a recent pooled 
analysis performed on 3300 patients receiving empagli-
flozin has shown its ability to reduce waist, total body fat 
and indexes of central and visceral adiposity, likely con-
tributing to reduce CV risk [22]. The sustained reduc-
tion of weight loss and HbA1c might have played a role 
in maintaining a lower CV risk along the whole duration 
of the trial [23].
BP reduction the significant drug-induced difference in 
systolic BP could potentially have strongly contributed 
to the results; this effect is also compatible with the early 
divergence of the survival curves, thus playing a major 
role in the improved prognosis of empagliflozin-treated 
patients. Against this hypothesis stands the observed 
trend toward an increased risk of non-fatal stroke; this 
is surprising because stroke is the macrovascular com-
plication that should mostly take advantage from BP 
reduction.
Uricosuric effect recently, the role of uric acid as deter-
minant of CV disease has been postulated [24], also in 
the light of an association between uric acid levels and 
HF [25]; some studies showed the beneficial effect of 
lowering uric acid on CV events [26, 27], even though 
data are still controversial [28] and mechanisms are still 
unknown. On this basis, the uricosuric effect of SGLT2 
inhibitors could be a potential candidate to explain CV 
protection even if perplexity remains with respect to the 
rapid onset of protection that makes difficult to sustain 
this metabolic hypothesis.
Inflammation an interesting phenomenon observed 
in the trial is the early opening of the rate of events, that 
makes unlikely an effect on the natural history of ath-
erosclerotic disease and its acute manifestations. The 
relatively low impact on MI and stroke seems to support 
this view. It should be noted that, up to date, the effect of 
SGLT2 inhibitors on systemic inflammation is unknown, 
even though data obtained in animal models show a 
reduced expression of tissue markers of inflammation 
and oxidative stress following SGLT2 inhibitors adminis-
tration at the level of the kidneys [29] and, more recently, 
of the β-cell, with reduced apoptosis and tissue expres-
sion of reactive oxygen species [30]. It is interesting to 
note the parallelism with the results of the PREDIMED 
study, in which the early effect on CV protection was 
ascribed to an anti-inflammatory impact of the Mediter-
ranean diet.
Glucoretic effect the beneficial CV effect could be 
explained by the reduction of the risk of heart failure and 
related cardiovascular risk condition, in particular sud-
den death [31]. This view is supported by the marked 
reduction (−35  %) of hospitalization for HF. If this is 
the case, the effect could be mediated by the reduction 
of plasma volume and cardiac pre-load driven by the glu-
coretic and natriuretic effect of the SGLT2 inhibitor, and 
is compatible with the early onset of the beneficial effect 
in the observational period. In our opinion this interpre-
tation is clinically relevant because it further reminds to 
health care professional the prognostic importance of HF 
in patients with T2DM also considering the fact that not 
only overt but also subclinical HF is a frequent finding 
and/or suspicion in our patients in the outpatient setting.
Anti-arrhythmic effect another factor explaining the 
rapid occurrence of CV protection induced by empa-
gliflozin could be an anti-arrhythmic effect, indirectly 
mediated by glucagon [32], whose release is increased by 
empagliflozin [33].
Increased cardiac ß-hydroxybutyrate uptake it may be 
hypothesized that under the above conditions of stimu-
lated glucagon release, mild, persistent hyperketonemia, 
like may occur during treatment with SGLT2 inhibitors 
as reported by Ferrannini et  al. [34], β-hydroxybutyrate 
may be freely taken up by the heart and oxidized in pref-
erence to fatty acids. This fuel selection may improve 
transduction of oxygen consumption into work efficiency 
at the mitochondrial level. In addition, the hemocon-
centration that typically follows SGLT2 inhibition likely 
enhances oxygen release to the tissues, thereby establish-
ing a powerful synergy with the metabolic substrate shift 
and finally explaining the beneficial cardiovascular effect 
observed in Empa-Reg outcome.
RAAS-mediated effect the vast majority of partici-
pants in the Empa-Reg outcome study were treated with 
RAAS active drugs. Combining the two regimens (RAAS 
blocking and SGLT2 inhibition), as already suggested to 
explain positive effects on the glomerular hemodynam-
ics and nephroprotection [35], might in principle activate 
the AT2 receptor and the Angiotensin 1–7 pathway, with 
an anti-proliferative, anti-inflammatory, anti-arrhythmic, 
vasodilatory effect.
Arterial stiffness empagliflozin has been reported to 
reduce arterial stiffness in normotensive T1DM individu-
als [36] and could contribute to the beneficial CV effects. 
In Empa-Reg outcome this parameter was not measured, 
therefore its potential role is hypothetical and not sup-
ported by experimental data at this stage.
Safety profile in the Empa‑Reg outcome study
The Empa-Reg outcome study showed a surprising safety 
profile across the whole line of previously reported 
potential adverse events and side effects. The most insidi-
ous one, diabetic ketoacidosis, occurred rarely (0.1  %), 
without difference between active treatment and pla-
cebo. Similarly, elderly patients, apparently those with 
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the lowest indication to use SGLT2 inhibitors, have taken 
advantage from the best prognosis, even though it will 
be important to better define the relationship between 
increased blood cells count and the small, not significant 
signal of risk of stroke. In parallel, patients with chronic 
kidney disease showed a documented prognostic benefit, 
similar to that of individuals with preserved renal func-
tion. Finally, the reported increased risk of genital tract 
infection was fully confirmed, though its impact on the 
need for drug withdrawal was small.
Approaching other SGLT2‑inhibitors studies
To answer the question whether or not this CV protec-
tion is a class effect, or is exclusive of empagliflozin is, at 
this stage, a difficult task. If we postulate that the benefi-
cial cardiovascular effect is mostly related to glucoretic/
natriuretic effect and consequent volume depletion with 
a parallel, additional reduction of systolic BP or if we con-
sider that it may be mediated via metabolic effects related 
to increased cardiac ketone bodies uptake and disposal 
it is likely that benefit can be considered a class-effect 
because they might be all able to induce these effects. 
Said that, different drugs may have different specificity 
for SGLT2 and SGLT1, opening to discussion and specu-
lation related to many other different potentially relevant 
effects in terms of CV protection making potentially dif-
ferent the effect of each single drug within the class. For 
this reason we believe that it is imperative to confirm the 
results of Empa-Reg outcome. In few years, results from 
DECLARE (dapagliflozin in patients with a lower CV risk 
patients) and CANVAS (canagliflozin in high CV risk 
individuals) studies will be available, confirming or deny-
ing the role of SGLT2 inhibitors as first-class anti-dia-
betic drugs able to manage residual CV risk up to reduce 
mortality, likely independently from their glucose-lower-
ing effect.
Which will be the impact on microvascular complications?
Forthcoming studies with other SGLT2 inhibitors should 
also address still open questions regarding the effect on 
microvascular complications. In fact, the anti-hypergly-
cemic effect of empagliflozin might still be unsatisfactory 
for many patients in a real-life context. In Empa-Reg out-
come the HbA1c reduction of 0.3–0.4 % from baseline to 
the end of the trial failing to achieve the general target 
of <7 %, which is recognized to guarantee a robust protec-
tion against the risk to develop microvascular complica-
tion, would maintain concern with respect to this clinical 
issue. When considering kidney disease, Empa-Reg renal 
will likely answer in a while; promising preliminary data, 
showing a stable glomerular filtration rate across the 
whole study duration vs a decline in the placebo arm, 
were shown at the American Society of Nephrology 2015 
annual meeting and we are waiting for the publication of 
the original article. This beneficial effect on diabetic kid-
ney disease may be selectively explained by the capacity 
of empagliflozin to prevent hyperfiltration in the early 
stage of diabetic nephropathy as reported in patients with 
type 1 diabetes [37]. The question about microvascular 
complication would remain open with respect to diabetic 
retinopathy and neuropathy in which mechanistically the 
above mentioned protective mechanism for the kidney 
may result to be irrelevant for the eyes and the peripheral 
nervous system.
Conclusion
Whatever would the future scenario be, Empa-Reg out-
come, with the strength of its results, can likely influence 
the modality how, in the last years, we have considered 
the available therapeutic options. Compared with other 
clinical trials, we face for the first time an anti-diabetic 
drug able to reduce the risk of death, CV death and HF. 
Such results have no precedents, and the clinician cannot 
ignore it.
The paradigm has changed after this study. When we 
figure out an Empa-Reg outcome-like T2DM patient, 
before Empa-Reg outcome we would ask ourselves which 
could have been the best “tailored” therapeutic inter-
vention, on the basis of his/her individual features (age, 
personal clinical history, diabetes duration, glycemic tar-
get, phenotype, lifestyle, presence of complications and/
or comorbidities). Now, we should establish whether in 
Empa-Reg-like patients there is any reason, except the 
presence of precise contra-indications to its use, for 
not considering the possibility to prescribe a drug able 
to improve the prognosis of our patient irrespective of 
its anti-hyperglycemic effect. What has been observed 
during the Empa-Reg outcome study remains, so far, an 
enigma, and it seems difficult to use a therapeutic instru-
ment without knowing the mechanism throughout it 
improves CV prognosis, especially when such protection 
does not seem to be mediated by atherosclerosis-related 
mechanisms.
We are in front of a single clinical trial, even robust and 
well-conducted. More data will be necessary to confirm 
these positive effects, perhaps providing instruments 
to understand what has exactly happened in Empa-Reg 
outcome.
However, such therapeutic approach should be seri-
ously considered because, in Empa-Reg outcome, body 
weight, BP, uric acid levels, risk of hypoglycemia, all go 
in the desired direction. The study also confirms a good 
safety profile, with the only concern of genital infections. 
Concerns on euglycemic diabetic ketoacidosis, hypogly-
cemia in the elderly, urinary infections, bone fractures, 
use in patients with impaired kidney function, vanished, 
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in the absence of an even minimal signal of danger. 
That is a striking difference when we refer to the alarms 
reported by FDA and EMA, and it will require a cautious 
clarification through future studies.
To conclude, several arguments can be provided either 
in favor of an enthusiastic or a more cautious interpre-
tation of the Empa-Reg outcome results: it is too early to 
pretend answering to all the points raised by the study. 
Trying a parallelism, similarly to how intensive vs con-
ventional treatment strategy trials had imposed a radical 
change in the therapeutic approach, Empa-Reg outcome 
challenges us, forcing to change again the clinical para-
digm followed in the last years. To be provocative, we 
might figure out to go back to more rigid and simple 
therapeutic schemes, with a potentially new hierarchy 
of drug choice to combine with metformin at least in 
patients with high CV risk.
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